Search the Newsreel

Sarepta Schedules 4:30 p.m. Call to Discuss Q2 Results

Rossari Biotech Q1FY27 revenue surges 28% to ₹697.2 crore

Samsara Inc. (NYSE: IOT) CAO sells 960 shares in 10b5-1 trade

Samsara Inc.'s Chief Accounting Officer, Benjamin Louis Kirchhoff, sold 960 shares of Class A Common Stock on July 20, 2026, for $37.70 per share. This sale was conducted under a Rule 10b5-1 trading plan adopted in September 2025. After the transaction, Kirchhoff retains 162,800 …

Bossard Holding AG (XSWX:BOSN) (Q2 2026) Earnings Call Highlights: Strong Growth Amid Currency ...

This article first appeared on GuruFocus. Sales: CHF575.7 million in the first half of 2026, a growth of 9.7% in local currency and 5.3% in Swiss francs. Gross Profit Margin: Increased by 11.7% to CHF198.3 million, with gross margin improving from 32.5% to 34.4%. …

SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space

Shares of Sarepta Therapeutics (SRPT) fell by 4% after Citi reiterated a 'Sell' rating due to anticipated heightened competition in the Duchenne muscular dystrophy (DMD) exon-skipping market. This comes as Dyne Therapeutics' DMD therapy, z-rostudirsen, received FDA application acceptance with Priority Review, potentially offering …

$66.26 Steak and Lobster Offerings Honor Caesars Palace's 1966 Opening

Caesars Palace is celebrating its 60th anniversary with limited-time culinary and cocktail experiences available through December 31. These offerings, spanning multiple acclaimed restaurants, are inspired by the resort's 1966 opening era, featuring vintage steakhouse favorites, French classics, and nostalgic buffet selections. Notably, Peter Luger …

Savor 60 Years of Caesars Palace with Limited-Time Dining and Cocktail Experiences Inspired by 1966

For more information on the anniversary offerings, guests can visit caesars.com/caesars-palace/60 LAS VEGAS, July 21, 2026--(BUSINESS WIRE)--Caesars Palace, one of the most iconic resorts on the Las Vegas Strip, is celebrating its 60th anniversary with limited-time culinary and cocktail experiences inspired by the flavors, …

Caesars Entertainment (CZR) Earnings Expected to Grow: Should You Buy?

The market expects Caesars Entertainment (CZR) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might …

Sarepta Therapeutics Stock Short Interest Rises to 32.62%

Sarepta Therapeutics (SRPT) experienced a rise in short interest to 32.62% of its float as of June 30th, according to new data. Institutional investors showed mixed activity, with 137 adding shares and 160 decreasing positions in Q1 2026, while insiders recorded one sale and …

Caesars Entertainment (CZR) Expected to Post Quarterly Earnings on Tuesday

Caesars Entertainment (CZR) is anticipated

Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ review

The FDA has accepted Dyne Therapeutics' application for its Duchenne muscular dystrophy therapy, zeleciment rostudirsen, setting a target action date of January 21, 2027. Analysts predict a smooth approval and significant market share due to its superior efficacy and more convenient dosing compared to …

Sarthak Metals fixes record date for 31st AGM

Sarama Resources Completes A$3.2M Sale of Western Australian Gold Assets to Riedel Resources

Samsara (IOT) Beat Q1 Expectations, Is The Stock Still Overvalued?

Sarytogan Graphite (ASX:SGA) Rises 5.00% as Graphite Development Strategy Continues to Advance

Sarepta Skids After A Rival Clears A Key Hurdle In The Duchenne Space

Sarepta stock took a hit after Dyne Therapeutics said the FDA would review its exon 51-skipping drug in Duchenne patients. Continue Reading

LENS stock trades on Nasdaq as investors weigh cataract device growth and recent financial trends

LENSAR Inc. (LENS) stock is trading on Nasdaq, reflecting investor interest in the ophthalmic device maker specializing in femtosecond laser systems for cataract surgery. The company is in a growth phase, showing modest but growing revenues alongside recurring operating losses due to significant R&D …

Dyne Therapeutics Trades Sideways Over An FDA Hurdle. Is It Time To Take Profits?

Dyne Therapeutics stock briefly jumped Monday after the FDA agreed to review the company's muscular dystrophy drug. Continue Reading

U.S. Consumer Sentiment Index Hits Five-Month High: 5 Top Picks

The U.S. Consumer Sentiment Index reached a five-month high in July, driven by a decline in energy costs. The University of Michigan reported an increase to 54.4 from 49.5 in June, exceeding the Zacks Consensus Estimate. This article highlights five consumer discretionary stocks—Cintas Corp., …

Caesars Entertainment stock trades steadily as Las Vegas recovery lifts Q1 revenue

Caesars Entertainment (US12738T1034) reported Q1 2026 revenue of approximately $2.7 billion and adjusted EBITDA of $850 million, reflecting continued recovery in Las Vegas and regional casino operations. The company's stock performance is balanced by improving fundamentals and investor caution due to its leverage and …

Caesarstone updates financial calendar with second-quarter results release, webcast call

Caesarstone (CSTE) has updated its financial calendar, announcing that its second-quarter 2026 earnings will be released on August 5, 2026, before market open. A webcast and conference call for investors and analysts is scheduled for the same day at 8:30 a.m. ET. A telephonic …

Vysarn Limited Reports Strong FY26 Financial Results and Acquisition of NewGround

Rossari Biotech Share Price Falls 2.27% After Q1 FY27 Results: What Is Driving the Move

Expect business margins about 77%-78% this fiscal: Essar Shipping Ports

Rossari Biotech registers PAT of Rs 35 crore in Q1 FY27

Rossari Biotech expects growth to pick up as new capacity comes online

Unpacking Q1 Earnings: Samsara (NYSE:IOT) In The Context Of Other Data Analytics Stocks

Has Sarepta Therapeutics (SRPT) Fallen Below Fair Value After FDA Progress?

Sarepta Therapeutics (SRPT) has experienced a significant decline in share price over the past three years. Despite recent FDA approval for its Duchenne muscular dystrophy therapies, the stock appears overvalued based on its P/E ratio, trading at 27.9x earnings compared to the biotech industry …

Samsara Stock And 2 Founder Led Software Picks With Real Revenue Growth

Sarthak Metals FY26 revenue rises 8% to ₹192.25 Crore

Samsara, Inc. Class A (IOT) Q3 2025 Earnings Report - Results, Call & Slides

Samsara, Inc. (IOT) reported its Q3 2025 earnings, exceeding analyst expectations with an actual EPS of $0.07 against a consensus of $0.04 and actual revenue of $321.98 million compared to an expected $310.56 million, marking a 35.55% year-over-year revenue growth. The company also announced …

Caesars Entertainment (NASDAQ:CZR) Upgraded by Zacks Research to "Hold" Rating

Zacks Research upgraded Caesars Entertainment (NASDAQ:CZR) from "strong sell" to "hold." This upgrade aligns with a generally cautious analyst outlook, and the stock currently holds a consensus Hold rating and a $31.00 price target. The company's Q1 revenue of $2.87 billion surpassed estimates, though …

Caesars Entertainment stock holds ground as Las Vegas demand and digital growth shape the next phase

Caesars Entertainment's stock performance reflects a balance between robust Las Vegas demand, recovering regional casinos, and significant investments in digital betting. While the company saw increased revenue in 2023, net income declined due to operating costs, interest expenses, and digital expansion, leading to margin …

Rossari Biotech consolidated net profit rises 4.46% in the June 2026 quarter

(CZR) Risk Channels and Responsive Allocation

This article provides an AI-driven analysis for Caesars Entertainment Inc. (NYSE: CZR), highlighting a neutral sentiment across all time horizons and an exceptional 38.7:1 risk-reward short setup. It details institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis, which …

Samsara CAO Benjamin Kirchhoff sells $96,403 in stock

Samsara's Chief Accounting Officer, Benjamin Louis Kirchhoff, sold 2,549 shares of Class A Common Stock for approximately $96,403 on July 15, 2026, under a pre-arranged trading plan. This transaction follows strong fundamental performance for Samsara, with positive analyst revisions and recent product advancements, including …